Life-threatening coagulopathy associated with use of campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery

American Journal of Transplantation

Volumn 8, Issue 4, 2008, Pages 884-886

  Ku, G ^a   Ting, W C ^a   Lim, S T K ^a   Lee, B T ^a   Calne, R Y ^b  

^a MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Campath; Coagulopathy; Renal transplant

Indexed keywords

ALEMTUZUMAB; CEFTRIAXONE; CHLORPHENIRAMINE MALEATE; CIPROFLOXACIN; COTRIMOXAZOLE; DOPAMINE; FLUCONAZOLE; FRESH FROZEN PLASMA; MEROPENEM; METHYLPREDNISOLONE; MOXIFLOXACIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID; TACROLIMUS; TRIMETHOPRIM; VALGANCICLOVIR; VANCOMYCIN;

ABDOMINAL BLEEDING; ADULT; ARTICLE; BLOOD; BLOOD CLOT RETRACTION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CASE REPORT; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DIURESIS; GRAFT DYSFUNCTION; HEMOSTASIS; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE INFECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; RESPIRATORY FAILURE; SURGICAL WOUND; THROMBIN TIME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BLOOD COAGULATION DISORDERS; BLOOD COMPONENT TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 40449142930     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02152.x     Document Type: Article

References (8)

1. Calne RY, Moffatt SD, Friend PJ et al. Campath 1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 68 : 1613 1616.
2. Calne RY, Friend PJ, Moffatt S et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 351 : 1701 1702.
3. Watson CJE, Bradley JA, Friend PJ, Calne R et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005 5 : 1347 1353.
4. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006 6 : 331 339.
5. Tzakis AG, Tryphonopoulos P, Kato T et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004 77 : 1209 1214.
6. Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - long-term results. Am J Transplant 2005 5 : 2539 2548.
7. Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 2004 78 : 966 971.
8. Moss VJ, Chay Ron, Ali Ijaz et al. Abnormal coagulation parameters in prednisone-free renal transplant recipients immediately after Campath induction. Am J Transplant 2006 6 (Suppl 2 956.